Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer

Study Overview
=================
Brief Summary
-----------------
This study will examine the combination of pembrolizumab and tadalafil for safety and efficacy in advanced head and neck cancer.

Detailed Description
-----------------
Immune competent animal models of HNSCC demonstrate that combination PDE-5 inhibitor (tadalafil) and PD-1 inhibitor therapy is more effective than either therapy alone based on the concept of targeting multiple immune repressive abnormalities simultaneously (PD-1 checkpoint and myeloid suppressive pathways). This trial will test the hypothesis that combination PD-1 inhibition and PDE-5 inhibition can be safely co-administered, and secondarily test the hypothesis that the combination of both therapies will be more effective than PD-1 inhibition alone in recurrent/metastatic HNSCC.

Official Title
-----------------
A Phase II Study of Tadalafil and Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Conditions
-----------------
Cancer, Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Head and Neck Carcinoma, Head and Neck Cancer Stage III, Head and Neck Cancer Stage IV, Head and Neck Cancer Metastatic, Cancer of Esophagus, Cancer, Metastatic, Cancer of Head and Neck, Cancer of Mouth, Cancer of Neck

Intervention / Treatment
-----------------
* Drug: Pembrolizumab
* Drug: Tadalafil


Participation Criteria
=================
Eligibility Criteria
-----------------
Selected Inclusion Criteria: Patients (at least 18 years of age) must have recurrent or metastatic squamous cell carcinoma of the head and neck. Presence of measurable disease. Life expectancy of greater than 12 weeks Patients must have normal organ and marrow function Selected Exclusion Criteria: Prior therapy with an PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting Uncontrolled central nervous system metastases (stable metastases permitted) Active autoimmune disease Chemotherapy ≤28 days prior to first administration of study treatment and/or monoclonal antibody ≤8 weeks prior to first administration of study treatment. Prior daily use of tadalafil or other long-acting PDE5 inhibitors for one month or greater within 3 months of trial enrollment Current use of all other long-acting PDE5 inhibitors. Known severe hypersensitivity to tadalafil or any of the excipients of this product Current treatment with nitrates Current systemic treatment with a potent cytochrome P450 3A4 (CYP3A4) inhibitor such as ketoconazole or ritonavir. Current treatment with guanylate cyclase (GC) stimulators such as riociguat. History of hypotension and/or blindness and/or sensorineural hearing loss during prior treatment with tadalafil or other PDE-5 inhibitors History of known hereditary degenerative retinal disorders, including retinitis pigmentosa Prior history of non-arteritic anterior ischemic optic neuropathy Pregnant or breastfeeding; a negative pregnancy test is required within 14 days of randomization for all women of childbearing potential. History of stroke within prior 6 months. History of acute myocardial infarction within prior 3 months, uncontrolled angina, uncontrolled arrhythmia, or uncontrolled congestive heart failure Left ventricular outflow obstructions, such as aortic stenosis and idiopathic hypertrophic subaortic stenosis Angina requiring treatment with long-acting nitrates Angina requiring treatment with short-acting nitrates within 90 days of planned tadalafil administration Unstable angina within 90 days of visit 1 (Braunwald 1989) Positive cardiac stress test without documented evidence of subsequent, effective cardiac intervention History of any of the following coronary conditions within 90 days of planned tadalafil administration: Myocardial Infarction Coronary artery bypass graft surgery Percutaneous coronary intervention (for example, angioplasty or stent placement) Any evidence of heart disease (NYHA ≥ Class II as defined in Protocol Attachment LVHG.3) within 6 months of planned tadalafil administration Concurrent systemic immunosuppressant therapy (e.g., cyclosporine A, tacrolimus, etc., or chronic administration of >10 mg/day of prednisone or equivalent) Prior organ transplantation Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Tadalafil and Pembrolizumab<br>Tadalafil for up to 12 months and pembrolizumab for up to 24 months. | Drug: Pembrolizumab<br>* 200 mg intravenously every 3 weeks<br>* Other names: Keytruda;Drug: Tadalafil<br>* 10 mg by mouth daily<br>* Other names: Cialis;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Dose Limiting Toxicity (DLT) | Rate of dose limiting toxicity at least possibly attributable to study treatment | 2 years | 
| Overall Survival (OS) | Overall survival at 12 months post-enrollment | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response measured by RECIST 1.1 |  | 12 months | 
| Progression free survival |  | 2 years | 
| Adverse event rates |  | 2 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
metastatic, cancer, pembrolizumab, tadalafil, cialis, opdivo, immunotherapy, carcinoma, pd-1, pde